Patients with Lung Cancer Followed by Breast Cancer Have a Better Prognosis than Patients with these Cancers in the Opposite Order due to Differences in Pathological Components
Objectives: To explore the prognostic differences between lung cancer followed by breast cancer (LFB) and breast cancer followed by lung cancer (BFL) and the reasons for the differences.
Methods: The database we chose was SEER 18 Regs, from which we retrieved data from patients diagnosed with multiple primary standardized incidence rate (MP-SIR) segments of cancer.
Results: A total of 7169 patients were included, of whom 979 were patients with LFB and 6190 were BFL patients. The proportion of small cell lung carcinoma in LFB was 4%, which was significantly lower than that in BFL (p<0.001), while the proportion of carcinoid carcinoma in LFB was significantly higher than that in BFL (p<0.001). Survival analysis of LFB and BFL showed a slightly better prognosis for the former than the latter (HR=0.871 (0.804-0.944)), and the difference was statistically significant (p<0.001). The difference was not statistically significant after adjustment for the pathological type of tumor (HR=0.911 (0.827-1.003), p=0.057).
Conclusion: LFB has a worse prognosis than BFL, and this difference is explained by the difference in the ratio of the two pathological components.
1.Shapiro CL. Cancer Survivorship. N Engl J Med 2018;379:2438– 50.
2. Feller L, Lemmer J. New 'second primary' cancers. SADJ 2012;67:175–8.
3. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019;69:363–85.
4. Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011;12:353–60.
5. Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 2016;122:3075–86.
6. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
7. Molina-Montes E, Requena M, Sánchez-Cantalejo E, Fernández MF, Arroyo-Morales M, Espín J, et al. Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. Gynecol Oncol 2015;136:158–71.
8. Kim BK, Oh SJ, Song JY, Lee HB, Park MH, Jung Y, et al; Korean Breast Cancer Society. Clinical Characteristics and Prognosis Associated with Multiple Primary Cancers in Breast Cancer Patients. J Breast Cancer 2018;21:62–9.
9. Moertel CG, Dockerty MB, Baggenstoss AH. Multiple primary malignant neoplasms. II. Tumors of different tissues or organs. Cancer 1961;14:231–7.
10. Lv M, Zhang X, Shen Y, Wang F, Yang J, Wang B, et al. Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors. Medicine (Baltimore) 2017;96:e6799.
11. Powell S, Tarchand G, Rector T, Klein M. Synchronous and metachronous malignancies: analysis of the Minneapolis Veterans Affairs (VA) tumor registry. Cancer Causes Control 2013;24:1565–73.
12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.
13. Wei JL, Jiang YZ, Shao ZM. Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study. Int J Clin Onco 2019;24:934–40.
14. Deng L, Harðardottír H, Song H, Xiao Z, Jiang C, Wang Q, et al. Mortality of lung cancer as a second primary malignancy: A population-based cohort study. Cancer Med 2019;8:3269–77.
15. Kinova S, Duris I. Carcinoid tumor. Bratisl Lek Listy 2001;102:495–504.
16. Mruthyunjayappa S, Zhang K, Zhang L, Eltoum IA, Siegal GP, Wei S. Synchronous and metachronous bilateral breast cancer: clinicopathologic characteristics and prognostic outcomes. Hum Pathol 2019;92:1–9.
17. Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK. Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results. Breast 2017;35:122–9.
18. Stovall M, Smith SA, Langholz BM, Boice JD Jr, Shore RE, Andersson M, et al; Women's Environmental, Cancer, and Radiation Epidemiology Study Collaborative Group. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys 2008;72:1021–30.
19. Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 2010;102:220–6.
20. Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and metaanalysis of 762,468 patients. Radiother Oncol 2015;114:56–65.
21. Neugut AI, Robinson E, Lee WC, Murray T, Karwoski K, Kutcher GJ. Lung cancer after radiation therapy for breast cancer. Cancer 1993;71:3054–7.
22. Mazonakis M, Stratakis J, Lyraraki E, Damilakis J. Risk of contralateral breast and ipsilateral lung cancer induction from forward-planned IMRT for breast carcinoma. Phys Med 2019;60:44–9.